Company news
Os Therapies Incorporated (AMEX:OSTX) news
Every Os Therapies Incorporated press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phas...
September 8, 2026
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
September 2, 2026
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
August 17, 2026
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention ...
August 13, 2026
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
July 8, 2026
OS Therapies Third Quarter 2026 Corporate Outlook
July 6, 2026
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
July 2, 2026
OS Therapies Provides U.S. Regulatory Update
June 30, 2026
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosar...
June 8, 2026
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metas...
June 2, 2026
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
May 29, 2026
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
May 26, 2026
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
May 18, 2026
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
May 15, 2026
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
May 14, 2026
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or ...
April 30, 2026
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
April 27, 2026
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
April 16, 2026
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
April 13, 2026
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
April 8, 2026
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
April 2, 2026
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and...
March 31, 2026
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory...
March 27, 2026
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in...
March 25, 2026
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
March 9, 2026
OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma
February 17, 2026
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
February 4, 2026
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteo...
February 2, 2026
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Re...
January 15, 2026
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
January 14, 2026
OS Therapies Enters into Warrant Inducement Agreements
January 12, 2026
OS Therapies Provides First Half 2026 Corporate Outlook
January 5, 2026
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of ...
December 15, 2025
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of O...
December 9, 2025
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
December 5, 2025
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
November 25, 2025
OS Therapies to Spinoff OS Animal Health into Standalone Public Company
November 20, 2025
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
November 17, 2025
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic ...
October 22, 2025
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurre...
October 17, 2025
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Preve...
October 10, 2025
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
October 9, 2025
OS Therapies to Participate in Fall 2025 Conferences and Events
October 7, 2025
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
September 30, 2025
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
September 19, 2025
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
September 12, 2025
OS Therapies to Participate in Upcoming Investor Conferences in September 2025
September 3, 2025
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 M...
September 2, 2025
OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2...
September 2, 2025
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesda...
August 27, 2025